Keros Therapeutics Inc (KROS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -24,186 | -58,744 | -51,804 | -31,507 | -15,885 |
| Depreciation Amortization | 113 | 378 | 274 | 171 | 80 |
| Accounts receivable | 18,000 | -18,000 | N/A | -100 | N/A |
| Accounts payable and accrued liabilities | -668 | 1,485 | 662 | -777 | 859 |
| Other Working Capital | 18,055 | -16,070 | 887 | -2,371 | 2,707 |
| Other Operating Activity | -12,741 | 28,803 | 7,398 | 6,442 | 1,734 |
| Operating Cash Flow | $-1,427 | $-62,148 | $-42,583 | $-28,142 | $-10,505 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -147 | -1,024 | -865 | -720 | -210 |
| Investing Cash Flow | $-147 | $-1,024 | $-865 | $-720 | $-210 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 118 | 28,550 | 134 | 99 | 42 |
| Financing Cash Flow | $118 | $28,550 | $134 | $99 | $42 |
| Beginning Cash Position | 231,369 | 265,991 | 265,991 | 265,991 | 265,991 |
| End Cash Position | 229,913 | 231,369 | 222,677 | 237,228 | 255,318 |
| Net Cash Flow | $-1,456 | $-34,622 | $-43,314 | $-28,763 | $-10,673 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,427 | -62,148 | -42,583 | -28,142 | -10,505 |
| Capital Expenditure | -147 | -1,024 | -865 | -720 | -210 |
| Free Cash Flow | -1,574 | -63,172 | -43,448 | -28,862 | -10,715 |